

Scottish Paediatric & Adolescent Rheumatology Network (SPARN)

Chickenpox Pathway

NOTE

This guideline is not intended to be construed or to serve as a standard of care. Standards of care are determined based on all clinical data available for an individual case and are subject to change as scientific knowledge and technology advance and patterns of care evolve. Adherence to guideline recommendations will not ensure a successful outcome in every case, nor should they be construed as including all proper methods of care or excluding other acceptable methods of care aimed at the same results. The ultimate judgement must be made by the appropriate healthcare professional(s) responsible for clinical decisions regarding a particular clinical procedure or treatment plan. This judgement should only be arrived at following discussion of the options with the patient, covering the diagnostic and treatment choices available. It is advised, however, that significant departures from the national guideline or any local guidelines derived from it should be fully documented in the patient's case notes at the time the relevant decision is taken.

This guidance has been prepared by NHS National Services Scotland (NSS) National Networks. Accountable to Scottish Government, NSS works at the heart of the health service providing national strategic services to the rest of NHSScotland and other public sector organisations to help them deliver their services more efficiently and effectively. Working across professional and organisational boundaries, National Networks support the delivery of safe, effective healthcare that's designed around patients, carers and families.

Review: March 2028 NSD610-013.11 V2

SPARN

Chickenpox Pathway


Rheumatology patient significantly exposed to chickenpox

- Play or direct contact (in the same room) with the index case >15 minutes during the infectious period (48 hours prior to rash developing, until vesicles all crusted over)
- Direct contact with exposed lesions of herpes zoster



Are they immunocompromised? Anyone treated with any of the following?

- <u>Steroids</u>*: Prednisolone equivalent dose 2mg/kg/day for 1 week or 1mg/kg/day for at least 1 month, in the last 3 months
- DMARD: Methotrexate, Azathioprine, Mycophenolate Mofetil, Ciclosporin, Cyclophosphamide, Leflunomide
- <u>Biologic</u>**: Etanercept, Infliximab, Adalimumab, Tocilizumab, Abatacept, Anakinra, Canakinumab, Rituximab, Sarilumab, Belimumab, Ixekizumab, Secukinumab, Baricitinib, Upadacitinib



References

- British Society for Paediatric & Adolescent Rheumatology. Standards of care for children and young people with Juvenile Idiopathic Arthritis. January 2009
- 2. Royal College of Paediatrics and Child Health. Best practice statement (Feb 2002) Immunisation of the Immunocompromised child. ISBN 1- 900954-67-2
- 3. Roderick M, Finn A, Ramanan AV. Chickenpox in the immunocompromised child. *Arch Dis Child* 2012;97(7):587-589
- Postexposure chickenpox prophylaxis in children with leukaemia: a reply to the recent PEP talk study and report of a service evaluation in a tertiary paediatric haematology centre in the UK. Samuelson CV, Rambani R, Vora AJ. Arch Dis Child. 2012 Aug;97(8):759-60
- 5. PEPtalk: postexposure prophylaxis against varicella in children with cancer. Arch Dis Child. 2011 Sep;96(9):841-5
- Clinical course and therapeutic approach to varicella zoster virus infection in children with rheumatic autoimmune diseases under immunosuppression, Raphael Leuvenink, Florence Aeschlimann, Walter Baer, Gerald Berthet, Elvira Cannizzaro, Michael Hofer, Daniela Kaiser, Silke Schroeder, Ulrich Heininger & Andreas Woerner Paediatric Rheumatology volume 14, Article number: 34 (2016)
- 7. The Green Book Information for public health professionals on immunisation. Immunisation against infectious disease: Varicella: the green book, chapter 34 26 June 2019 Guidance

Aciclovir (Acyclovir)

https://doi-org.knowledge.idm.oclc.org/10.18578/BNFC.394758880 Last update September 2022

All content is available under the <u>Open Government Licence v3.0</u> except for graphic assets and where otherwise stated.'

Contact Email Address: nss.sparn@nhs.scot

Review: March 2028 NSD610-013.11 V2